WallStSmart

Boston Scientific Corp (BSX)vsViking Holdings Ltd (VIK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 217% more annual revenue ($20.61B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 17.3%. BSX trades at a lower P/E of 23.7x. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

VIK

Strong Buy

66

out of 100

Grade: B-

Growth: 9.3Profit: 8.5Value: 4.7Quality: 4.3
Piotroski: 6/9Altman Z: 0.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued

Intrinsic value data unavailable for VIK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

VIK4 strengths · Avg: 9.0/10
Return on EquityProfitability
254.5%10/10

Every $100 of equity generates 255 in profit

EPS GrowthGrowth
226.6%10/10

Earnings expanding 226.6% YoY

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

Revenue GrowthGrowth
27.8%8/10

Revenue surging 27.8% year-over-year

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

VIK3 concerns · Avg: 2.7/10
P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
33.7x2/10

Trading at 33.7x book value

Altman Z-ScoreHealth
0.162/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : VIK

The strongest argument for VIK centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : VIK

The primary concerns for VIK are P/E Ratio, Price/Book, Altman Z-Score.

Key Dynamics to Monitor

BSX profiles as a mature stock while VIK is a growth play — different risk/reward profiles.

VIK carries more volatility with a beta of 1.57 — expect wider price swings.

VIK is growing revenue faster at 27.8% — sustainability is the question.

VIK generates stronger free cash flow (675M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 66/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Viking Holdings Ltd

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.

Want to dig deeper into these stocks?